Evidence map›Paper›PMID 30881589›Full record

ArticleOxidative medicine and cellular longevity2019

Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway.

Hong Sun, Xi Guo, Ziteng Wang, Peipei Wang, Zhe Zhang, Jihong Dong, Rongyuan Zhuang, Yuhong Zhou, Guo Ma, Weimin Cai

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. The Therapeutic Potential of Antioxidants in Chemotherapy-Induced Peripheral Neuropathy: Evidence from Preclinical and Clinical Studies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  7. Review
  8. Article
  9. VANL-100 Attenuates Beta-Amyloid-Induced Toxicity in SH-SY5Y Cells.International journal of molecular sciences · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Pain Relieving and Neuroprotective Effects of Non-opioid Compound, DDD-028, in the Rat Model of Paclitaxel-Induced Neuropathy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  19. Article
  20. 7β-(3-Ethyl-Molecules (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hong SunDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China.
Xi GuoDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ziteng WangDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China.
Peipei WangDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China.
Zhe ZhangDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China.
Jihong DongDepartment of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Rongyuan ZhuangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yuhong ZhouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Guo MaDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China.ORCID 0000-0001-5524-7172
Weimin CaiDepartment of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China.ORCID 0000-0002-0342-4912
Fudan University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral neuropathy is the major dose-limiting side effect of paclitaxel (PTX), affecting both the quality of life and the survival of cancer patients. Nab-paclitaxel (nab-PTX) was developed to provide additional clinical benefits and overcome the safety drawbacks of solvent-based PTX. However, the prevalence of peripheral neuropathy induced by nab-PTX was reported higher than that induced by solvent-based PTX. Upon investigation, oxidative stress plays a major role in the toxicity of nab-PTX. In order to assess if the antioxidant alphalipoic acid (

Indexed as

AlbuminsAnimalsAntioxidantsMaleNF-E2-Related Factor 2Oxidative StressPaclitaxelPeripheral Nervous System DiseasesRatsRats, Sprague-DawleySignal TransductionThioctic Acid130-nm albumin-bound paclitaxelAlbuminsAntioxidantsNF-E2-Related Factor 2PaclitaxelThioctic Acid

Identifiers

PMID30881589
PMCPMC6387730
OpenAlexW2913596643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.